Provided by Tiger Fintech (Singapore) Pte. Ltd.

Amicus Therapeutics

8.90
0.0000
Post-market: 8.930.0300+0.34%19:59 EDT
Volume:4.91M
Turnover:44.14M
Market Cap:2.74B
PE:-71.65
High:9.17
Open:8.90
Low:8.81
Close:8.90
52wk High:12.65
52wk Low:5.51
Shares:308.24M
Float Shares:288.21M
Volume Ratio:1.19
T/O Rate:1.70%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1242
EPS(LYR):-0.1843
ROE:-22.62%
ROA:2.00%
PB:13.43
PE(LYR):-48.28

Loading ...

Amicus Therapeutics to Announce Third Quarter 2025 Financial Results on November 4, 2025

GlobeNewswire
·
Oct 23

How Strong Q2 Results and Pipeline Progress at Amicus Therapeutics (FOLD) Have Changed Its Investment Story

Simply Wall St.
·
Oct 17

A Look at Amicus Therapeutics (FOLD) Valuation Following Renewed Analyst Optimism and Upgraded Earnings Outlook

Simply Wall St.
·
Oct 12

Amicus Therapeutics Shares Rise After Upgrade From Needham

MT Newswires Live
·
Sep 19

Needham Upgrades Amicus Therapeutics to Buy From Hold, Price Target is $14

MT Newswires Live
·
Sep 18

Amicus Therapeutics Raised to Buy From Hold by Needham

Dow Jones
·
Sep 18

Amicus Therapeutics Inc : Needham Raises to Buy From Hold

THOMSON REUTERS
·
Sep 18

Should New Four-Year Pompe Data Shape Strategy for Amicus Therapeutics (FOLD) Investors?

Simply Wall St.
·
Sep 18

Positive Outlook for Amicus Therapeutics Amid Legal Developments and Patent Confidence

TIPRANKS
·
Sep 17

Jefferies says Galafold summary judgment as expected, may facilitate settlement

TIPRANKS
·
Sep 17

A Look at Amicus Therapeutics's Valuation After New 4-Year PROPEL Study Results

Simply Wall St.
·
Sep 14

Amicus Therapeutics Unveils Promising 4-Year Data for Pombiliti® + Opfolda® in Late-Onset Pompe Disease Study at ICIEM

Reuters
·
Sep 08

Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2025

GlobeNewswire
·
Aug 29

Earnings Flash (FOLD) Amicus Therapeutics Posts Q2 Net Sales $154.7M, vs. FactSet Est of $146.7M

MT Newswires Live
·
Jul 31

Earnings Flash (FOLD) Amicus Therapeutics Posts Q2 Adjusted EPS $0.01, vs. FactSet Est of $0.02

MT Newswires Live
·
Jul 31

Stock Track | Amicus Therapeutics Soars 5.87% Pre-Market on Impressive Q2 Earnings Beat and Strong Outlook

Stock Track
·
Jul 31

Amicus Therapeutics' Q2 revenue up more than expected on Galafold demand

Reuters
·
Jul 31

Amicus Therapeutics Q2 Revenue USD 154.7 Million Vs. IBES Estimate USD 147.1 Million

Reuters
·
Jul 31

Amicus Therapeutics Q2 Adj. EPS $0.01 Beats $(0.11) Estimate, Sales $154.688M Beat $147.399M Estimate

Benzinga
·
Jul 31

Amicus Therapeutics Q2 EPS USD -0.08

THOMSON REUTERS
·
Jul 31